Schedule Update - effective 1 January 2012 (text extract)

This is the text extract for Schedule Update - effective 1 January 2012, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 January 2012

Section H cumulative for December 2011 and January 2012

Contents

Summary of Pharmac decisions effective 1 January 2012 ........................... 3 Subsidy changes for some respiratory inhalation products and access restrictions to combination inhalers – 1 February 2012 ............... 4 Paracetamol tablets reference priced ............................................................ 5 crc news on paracetamol oral liq 120 mg per 5 ml ..................................... 5 Dentist controlled drug prescriptions clarification ......................................... 5 New brand of atorvastatin subsidised ........................................................... 6 clinicians Newsletter ..................................................................................... 6 News in Brief ................................................................................................. 6 Tender News .................................................................................................. 8 Looking Forward ........................................................................................... 8 Sole Subsidised Supply products cumulative to January 2012 ..................... 10 New Listings ................................................................................................ 20 changes to restrictions ............................................................................... 21 changes to Subsidy and manufacturer’s Price............................................. 25 changes to Sole Subsidised Supply ............................................................. 27 Delisted Items ............................................................................................. 28 Items to be Delisted .................................................................................... 29 Section h changes to Part II ........................................................................ 30 Section h changes to General rules ............................................................ 34 Index ........................................................................................................... 35

Summary of PharmaC decisions

effeCtIve 1 JaNUarY 2012 New listings (page 20) • atorvastatin (Dr reddy’s atorvastatin) tab 10 mg, 20 mg, 40 mg and 80 mg • Glyceryl trinitrate (Glytrin) aerosol spray 400 µg per dose, 250 dose OP – up to 250 dose available on a PSO • cefazolin sodium (aFT) inj 500 mg and 1 g – subsidy by endorsement for dialysis or cystic fibrosis patients • cefuroxime sodium (m-cefuroxime) inj 750 mg – maximum of 1 inj per prescription; can be waived by endorsement • Sulindac (aclin) tab 100 mg and 200 mg, 50 tab packs – additional subsidy by Special authority • Temozolomide (Temaccord) cap 5 mg, 20 mg, 100 mg and 250 mg – Special authority – retail pharmacy Changes to restrictions (pages 21-24) • Standard Supplements powder and liquid – amended Special authority criteria – removal of reference to manual applications • Extensively hydrolysed formula (Pepti Junior Gold) powder – amended Special authority criteria Decreased subsidy (pages 25-26) • clarithromycin (Klacid and Klamycin) tab 250 mg • Fluconazole (Pacific) cap 50 mg, 150 mg and 200 mg • Paracetamol (Pharmacare) tab 500 mg • Timolol maleate (apo-Timop) eye drops 0.25 %, 5 ml OP and 0.5 %, 5 ml OP • Bimatoprost (Lumigan) eye drops 0.03%, 3 ml OP Increased subsidy (pages 25-26) • Folic acid (Biomed) oral liq 50 µg per ml, 25 ml OP • amiloride (Biomed) oral liq 1 mg per ml, 25 ml OP • methyldopa (Prodopa) tab 125 mg, 250 mg and 500 mg • Spironolactone (Biomed) oral liq 5 mg per ml, 25 ml OP • chlorothiazide (Biomed) oral liq 50 mg per ml, 25 ml OP • Dexamethasone (Biomed) oral liq 1 mg per ml, 25 ml OP • Triamcinolone acetonide (Kenacort-a and Kenacort-a40) inj 10 mg per ml, 1 ml and 40 mg per ml, 1 ml • Trimethoprim (TmP) tab 300 mg • metronidazole (Trichozole) tab 200 mg and 400 mg • Doxepin hydrochloride (anten) tab 10 mg, 25 mg and 50 mg • Nortriptyline hydrochloride (Norpress) tab 10 mg and 25 mg • clonazepam (Paxam) tab 500 µg and 2 mg • Betahistine dihydrochloride (Vergo 16) tab 16 mg

4 Pharmaceutical Schedule - Update News

Subsidy changes for some respiratory inhalation products and access restrictions to combination inhalers – 1 February 2012

Scheduled subsidy and restriction changes will occur to some respiratory inhalation products from 1 February 2012. The changes are summarised below: • Removal of the Special Authority requirement for patients to be on separate ICS and LABA inhalers for at least three months prior to being eligible for funded combination inhalers. • Fully funding fluticasone powder for inhalation (Flixotide Accuhaler). • Reduction in the subsidies payable for: a) budesonide with eformoterol ICS and LABA combination inhalers (Symbicort Turbuhaler and Vannair) and salmeterol (Serevent) inhalers and b) eformoterol fumarate (Oxis and Foradil) inhalers. Reduction in subsidy will result in patient part charges for Symbicort Turbuhaler, Vannair, Oxis Turbuhaler and Foradil should the suppliers not reduce prices to match the new subsidies. Alternative fully funded products will include fluticasone with salmeterol (Seretide, Seretide Accuhaler) and salmeterol (Serevent and Serevent Accuhaler). To assist the implementation of these changes Symbicort Turbuhaler and Oxis Turbuhaler will remain fully funded for existing patients (patients dispensed Symbicort Turbuhaler or Oxis Turbuhaler prior to 1 July 2011) until 1 February 2012. Repeat dispensings for prescriptions with an initial dispensing before 1 February 2012 will also be fully funded. This will give clinicians and patients time to make a change to fully funded pharmaceuticals in the event that the supplier does not reduce its prices and patients wish to receive a fully funded product. These changes have previously been notified to the market. Please refer to the full notification located on the PHARMAC website for further details. http://www. pharmac.govt.nz/healthpros/notification

Pharmaceutical Schedule - Update News

Paracetamol tablets reference priced

We are transitioning the funded brand of paracetamol 500 mg tablets to Parafast from Pharmacare. As part of the transition, the Pharmacare brand of paracetamol 500 mg tablets will have a subsidy reduction from 1 January 2012. API have notified that it has dropped its price to match the subsidy so Pharmacare 500 mg tablets will remain fully subsidised until it is delisted from the Pharmaceutical Schedule on 1 April 2012.

CRC news on paracetamol oral liq 120 mg per 5 ml

Multichem, the supplier of Ethics Paracetamol Oral Suspension 120mg/5mL, will be changing the bottle it is supplied in, once the current stocks have been depleted. Supply of the new bottle is expected from approximately May 2012. The new bottle will have a wider neck size which will fit a NZ CRC (size 28). Some concerns have also been raised with regard to the volume of paracetamol suspension in the bottle. Investigations have demonstrated that the manufacturer is meeting all GMP fill volume requirements for Ethics Paracetamol Oral Suspension 120mg/5mL, 500ml. Tests demonstrate a fill volume range between 505ml to 510ml. Difficulty in pouring a full 500ml volume from the original bottle arises due to some residual product remaining on the inner walls of the bottle upon emptying. This occurs due to the higher viscosity of the suspension formulation. Multichem is investigating options to remedy this wastage.

Dentist controlled drug prescriptions clarification

Some changes were implemented via the Medicines Amendment Regulations 2011 from 1 December 2011. These amendments included changes to dentists' period of supply. We have received some queries on how this applies to the subsidy periods for controlled drugs. There have been no changes to the period of supply for controlled drugs as the Misuse of Drugs Act and Regulations have not been amended. Under the Misuse of Drugs Regulations 1977, dentists may only prescribe up to 7 days supply of a controlled drug (including a Class C controlled drug) for a patient under their care. The general rules in the Pharmaceutical Schedule further state that only 5 days supply of a Class B controlled drug will be subsidised when it is prescribed by a dentist.

Pharmaceutical Schedule - Update News

New brand of atorvastatin subsidised

The Dr Reddy’s brand of atorvastatin 10 mg, 20 mg, 40 mg and 80 mg tablets will be subsidised from 1 January 2012. Please note that this listing is an alternative brand and does not affect the subsidy for Lipitor at this time.

Clinicians Newsletter

Every month the PHARMAC Clinicians’ Newsletter is emailed to subscribers. This handy newsletter contains subsidy changes, items of interest to clinicians, upcoming events and changes, as well as updates on the PHARMAC Seminar Series. Copies are available on the PHARMAC website, or you can subscribe to have emailed directly to you. Please note that subscriptions are open to everyone, not just prescribers. Please refer to the PHARMAC website for subscription details – www.pharmacy.govt. nz/heathpros/CliniciansNews.

News in Brief

• The Apotex brand of clarithromycin 500 mg tablets (Apo-Clarithromycin) was listed fully subsidised from 1 November 2011 as a result of a Tender agreement. Due to a potential out-of-stock, reference pricing and Sole Supply has been delayed. Supplies of Apo-Clarithromycin 500 mg tablets will be in the market late December 2011. Reference pricing will occur on Klamycin tab 500 mg from 1 March 2012 and Apo-Clarithromycin tab 500 mg will have Sole Supply Status from 1 June 2012. Klamycin tab 500 mg will be delisted from 1 June 2012. ApoClarithromycin 500 mg tablets will have Hospital Sole Supply from 1 April 2012. Please note that this delay does not effect the Tender timelines for clarithromycin 250 mg tablets. • Special Authority applications for the Special Food category Standard Supplements, form number SA1104, will be able to be processed electronically for all application categories from 1 January 2012. Electronic Special Authorities for the “Adults” initial application criteria have been unable to be processed electronically. As part of the electronic Special Authority maintenance by the Ministry of Health this has been fixed and electronic applications can now be made. • Omezol Relief 10 mg, 20 mg and 40 mg capsules will be the Sole Subsidised Supply brand of omeprazole from 1 January 2012. The Dr Reddy’s Omeprazole brand will be delisted from 1 January 2012. • Due to a shortage of the Hospital Supply Status brand of the Pharmaceutical Cancer

Pharmaceutical Schedule - Update News

Treatment gemcitabine hydrochloride 1 g injection (Gemcitabine Ebewe) the DBL Gemcitabine brand was listed from 14 December 2011. Funding for gemcitabine hydrochloride carries the restriction of PCT only – Specialist and is subject to Special Authority approval. • Sanofi-Aventis has notified of its intention to discontinue Dimetriose (gestrinone) 2.5 mg capsules from approximately August 2012. Manufacture of the active ingredient is being discontinued globally. Current stock supply available will expire at the end of October 2012. • Mylan are changing the brand name and pack size for sulindac 100 mg and 200 mg

tablets from Daclin to Aclin from 1 January 2012. The new Aclin brand will be available in bottles of 50 tablets. Daclin will be delisted from 1 July 2012. • Cefaclor Sandoz brand of cefaclor monohydrate cap 250 mg was listed fully subsidised from 1 March 2011 as a result of a Tender agreement. Last month we notified via the December 2011 Update that reference pricing and Sole Supply would occur early to mid 2012. This decision has been delayed again due to supply issues. We will notify the market when we have confirmation of listing, reference price and sole supply and delisting dates.

tender News

Sole Subsidised Supply changes – effective 1 February 2012

Chemical Name Bicalutamide Finasteride Paracetamol with codeine Pravastatin Pravastatin Terbinafine Presentation; Pack size Tab 50 mg; 28 tab Tab 5 mg; 30 tab Tab paracetamol 500 mg with codeine phosphate 8 mg; 100 tab Tab 20 mg; 30 tab Tab 40 mg; 30 tab Tab 250 mg; 14 tab Sole Subsidised Supply brand (and supplier) Bicalaccord (Arrow) Rex Medical (Rex Medical) Paracetamol + Codeine (Relieve) (Mylan) Cholvastin (Douglas) Cholvastin (Douglas) Dr Reddy's Terbinafine (Dr Reddy's)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for implementation 1 february 2012 • Budesonide with eformoterol (Symbicort Turbuhaler and Vannair) and eformoterol fumarate (Oxis) – remove endorsement for full subsidy • Budesonide with eformoterol (Symbicort Turbuhaler and Vannair) – repeats fully subsidised where initial dispensing is prior to 1 February 2012 • Eformoterol fumarate (Oxis) – repeats fully subsidised where initial dispensing is prior to 1 February 2012 • Budesonide 100 µg with eformoterol fumarate 6 µg (Vannair) and 200 µg with eformoterol fumarate 6 µg (Vannair) – subsidy decrease • Budesonide 100 µg with eformoterol fumarate 6 µg (Symbicort Turbuhaler 100/6); 200 µg with eformoterol fumarate 6 µg (Symbicort Turbuhaler 200/6) and 400 µg with eformoterol fumarate 12 µg (Symbicort Turbuhaler 400/12) – subsidy decrease • Eformoterol fumarate (Oxis Turbuhaler) 6 µg – subsidy decrease • Eformoterol fumarate (Foradil ) 12 µg – subsidy decrease • Fluticasone (Flixotide accuhaler) 50 µg – subsidy increase

Possible decisions for implementation 1 february 2012 (continued) •combination Inhaled corticosteroids with Long-acting Beta-adrenoceptor agonist Inhaler– amend the Special authority criteria to remove 3 month trial period from the Special authority criteria. • cefuroxime sodium (mylan) inj 1.5 g – new listing and amendment to hospital listing date • Insulin glargine (Lantus) – remove prescriber note

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Abacavir sulphate Acarbose Acetazolamide Aciclovir Amantadine hydrochloride Aminophylline Amitriptyline Amlodipine Amoxycillin

Presentation

Oral liq 20 mg per ml Tab 300 mg Tab 50 mg & 100 mg Tab 250 mg Tab dispersible 200 mg, 400 mg & 800 mg Cap 100 mg Inj 25 mg per ml, 10 ml Tab 25 mg & 50 mg Tab 5 mg & 10 mg Inj 250 mg, 500 mg & 1 g Cap 250 mg & 500 mg Grans for oral liq 250 mg per 5 ml Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Crm Tab 100 mg Tab 100 mg Tab dispersible 300 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Tab 50 mg Inj 50 mg Tab 500 mg Tab 10 mg Tab 2.5 mg & 5 mg Inj 600 mg Scalp app 0.1% Eye drops 0.5% Eye drops 0.25% Tab 5 mg Crm, aqueous, BP Lotn, BP Inj 100 iu per ml, 1 ml Cap 0.25 µg & 0.5 µg

Brand Name Expiry Date*

Ziagen Ziagen Glucobay Diamox Lovir Symmetrel DBL Aminophylline Amitrip Apo-Amlodipine Ibiamox Alphamox Ospamox Curam Curam 2014 2012 2014 2013 2014 2014 2014 2014 2014 2013 2012 2012

Amoxycillin clavulanate

Aqueous cream Ascorbic acid Aspirin Atenolol Atropine sulphate Azathioprine Azithromycin Baclofen Bendrofluazide Benzylpenicillin sodium (Penicillin G) Betamethasone valerate Betaxolol hydrochloride Bisacodyl Calamine Calcitonin Calcitriol

AFT Vitala-C Ethics Aspirin EC Ethics Aspirin Atenolol Tablet USP AstraZeneca Imuprine Imuran Arrow-Azithromycin Pacifen ArrowBendrofluazide Sandoz Beta Scalp Betoptic Betoptic S Lax-Tab healthE API Miacalcic Airflow

2014 2013 2013 2012 2012 2013 2012 2012 2014 2014 2012 2014 2013 2012 2014 2012

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Calcium carbonate Calcium folinate Captopril Cefaclor monohydrate Ceftriaxone sodium Cephalexin monohydrate Cetomacrogol Cetirizine hydrochloride Chloramphenicol Chlorhexidine gluconate Ciclopiroxolamine Cilazapril Cilazapril with hydrochlorothiazide Citalopram hydrobromide Clobetasol propionate

Presentation

Tab eff 1.75 g (1 g elemental) Tab 15 mg Tab 12.5 mg, 25 mg & 50 mg Oral liq 5 mg per ml Grans for oral liq 125 mg per 5 ml Inj 500 mg Inj 1 g Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Crm BP Oral liq 1 mg per ml Tab 10 mg Eye drops 0.5% Eye oint 1% Soln 4% Handrub 1% with ethanol 70% Nail soln 8% Tab 0.5 mg, 2.5 mg & 5 mg Tab 5 mg with hydrochlorothiazide 12.5 mg Tab 20 mg Crm 0.05% Oint 0.05% Scalp app 0.05% TDDS 2.5 mg, 100 µg per day TDDS 5 mg, 200 µg per day TDDS 7.5 mg, 300 µg per day Inj 150 µg per ml, 1 ml Tab 25 µg Tab 150 µg Tab 75 mg Crm 1% Vaginal crm 1% with applicator Vaginal crm 2% with applicator Soln BP Tab 500 µg Powder for soln for oral use 4.4 g Crm 10% Tab 50 mg Tab 50 mg

Brand Name Expiry Date*

Calsource DBL Leucovorin Calcium m-Captorpril Capoten Ranbaxy-Cefaclor Veracol Aspen Ceftriaxone Cefalexin Sandoz Cefalexin Sandoz PSM Cetirizine - AFT Zetop Chlorafast Chlorsig Orion healthE Batrafen Zapril Inhibace Plus Arrow-Citalopram Dermol Dermol Dermol Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3 Catapres Dixarit Catapres Apo-Clopidogrel Clomazol Clomazol Clomazol Midwest Colgout Electral Itch-Soothe Nausicalm Cycloblastin 2014 2014 2013 2013 2013 2012 2013 2014 2012 2014 2012 2012 2013 2013 2014 2012

Clonidine

2012

Clonidine hydrochloride

2012

Clopidogrel Clotrimazole

2013 2014 2013 2013 2013 2013 2012 2012 2013

Coal tar Colchicine Compound electrolytes Crotamiton Cyclizine hydrochloride Cyclophosphamide

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Cyproterone acetate Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone Dexamethasone sodium phosphate

Presentation

Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs Nasal spray 10 µg per dose Eye oint 0.1% Eye drops 0.1% Inj 4 mg per ml, 1 ml & 2 ml

Brand Name Expiry Date*

Siterone Ginet 84 Desmopressin-PH&T Maxidex Maxidex Hospira Maxitrol Maxitrol 2012 2014 2014 2014 2013 2013 2014

Dexamethasone with neomycin Eye oint 0.1% with neomycin sulphate and polymyxin b sulphate 0.35% and polymyxin B sulphate 6,000 u per g Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml Dextrose Dextrose with electrolytes Inj 50%, 10 ml Soln with electrolytes

Biomed Pedialyte – Fruit Pedialyte – Bubblegum Pedialyte – Plain Voltaren Voltaren Ophtha Voltaren Diclofenac Sandoz DHC Continus Dilzem Cardizem CD Pytazen SR Laxofast 50 Laxofast 120 Laxsol Donepezil-Rex Apo-Doxazosin Doxine AFT Arrow-Enalapril Clexane Comtan DBL Ergometrine

2014 2013

Diclofenac sodium

Inj 25 mg per ml, 3 ml Eye drops 1 mg per ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab EC 25 mg & 50 mg Tab long-acting 60 mg Tab 30 mg & 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab long-acting 150 mg Cap 50 mg Cap 120 mg Tab 50 mg with total sennosides 8 mg Tab 5 mg & 10 mg Tab 2 mg & 4 mg Tab 100 mg Oint BP Tab 5 mg, 10 mg & 20 mg Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Inj 500 µg per ml, 1 ml

2014

2012 2013 31/12/11

Dihydrocodeine tartrate Diltiazem hydrochloride

Dipyridamole Docusate sodium Docusate sodium with sennosides Donepezil hydrochloride Doxazosin mesylate Doxycycline hydrochloride Emulsifying ointment Enalapril Enoxaparin sodium (low molecular weight heparin) Entacapone Ergometrine maleate

2014 2014 2013 2012 2014 2014 2014 2012 2012 2012 2014

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Erythromycin ethyl succinate Escitalopram Ethinyloestradiol Etidronate disodium Exemestane Felodipine Fentanyl

Presentation

Tab 400 mg Tab 10 mg & 20 mg Tab 10 µg Tab 200 mg Tab 25 mg Tab long-acting 5 mg Tab long-acting 10 mg Transdermal patch 12.5 µg per hour, 25 µg per hour, 50 µg per hour, 75 µg per hour, 100 µg per hour Inj 50 µg per ml, 2 ml & 10 ml Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) Inj 250 mg, 500 mg & 1 g Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Eye drops 0.1% Cap 20 mg Tab dispersible 20 mg, scored Tab 250 mg Metered aqueous nasal spray, 50 µg per dose Inj 10 mg per ml, 2 ml Tab 40 mg Crm 2% Oint 2% Cap 100 mg, 300 mg & 400 mg Tab 600 mg Inj 40 mg per ml, 2 ml Tab 80 mg Liquid TDDS 5 mg & 10 mg Tab 600 µg Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Crm 1% Powder Inj 50 mg per ml, 1 ml Tab 5 mg & 20 mg

Brand Name Expiry Date*

E-Mycin Loxalate NZ Medical and Scientific Arrow-Etidronate Aromasin Felo 5 ER Felo 10 ER Mylan Fentanyl Patch Boucher and Muir Ferodan Flucloxin AFT AFT AFT FML Fluox Fluox Flutamin Flixonase Hayfever & Allergy Frusemide-Claris Diurin 40 Foban Foban Nupentin Lipazil Pfizer Apo-Gliclazide healthE Nitroderm TTS Lycinate Serenace Serenace Serenace Pharmacy Health ABM Solu-Cortef Douglas 2012 2013 2012 2012 2014 2012 2013

Fentanyl citrate Ferrous sulphate Flucloxacillin sodium

2012 2013 2014 2012

Fluorometholone Fluoxetine hydrochloride Flutamide Fluticasone propionate Furosemide Fusidic acid Gabapentin Gemfibrozil Gentamicin sulphate Gliclazide Glycerol Glyceryl trinitrate Haloperidol

2012 2013 2013 31/1/13 2013 2012 2013 31/7/12 2013 2012 2014 2013 2014 2013

Hydrocortisone

2014 2013 2012

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Hydrocortisone acetate Hydrocortisone with miconazole Hydrocortisone with wool fat and mineral oil Hydroxocobalamin Hydroxychloroquine sulphate Hyoscine N-butylbromide Ibuprofen Imiquimod Indapamide Ipratropium bromide

Presentation

Rectal foam 10%, CFC-free (14 applications) Crm 1% with miconazole nitrate 2% Lotn 1% with wool fat hydrous 3% and mineral oil Inj 1 mg per ml, 1 ml Tab 200 mg Inj 20 mg, 1 ml Tab 10 mg Tab long-acting 800 mg Oral liq 100 mg per 5 ml Crm 5% Tab 2.5 mg Aqueous nasal spray, 0.03%, 15 ml OP Nebuliser soln, 250 µg per ml, 1 ml & 2 ml Inj 50 mg per ml, 2 ml Tab 20 mg Tab long-acting 40 mg Cap 10 mg & 20 mg Cap 100 mg Shampoo 2% Oral liq 10 g per 15 ml Oral liq 10 mg per ml Tab 150 mg Eye drops 50 µg per ml Tab 2.5 mg Subdermal implant (2 x 75 mg rods) Viscous soln 2% Inj 1%, 5 ml & 20 ml Crm 2.5% with prilocaine 2.5% (5 g tubes) Crm 2.5% with prilocaine 2.5%; 30 g OP Tab 5 mg, 10 mg & 20 mg Cap 250 mg Eye drops 0.1%

Brand Name Expiry Date*

Colifoam Micreme H DP Lotn HC ABM Hydroxocobalamin Plaquenil Buscopan Gastrosoothe Brufen SR Fenpaed Aldara Dapa-Tabs Univent Univent Ferrum H Ismo 20 Corangin Oratane Itrazole Sebizole Laevolac 3TC 3TC Hysite Letara Jadelle Xylocaine Viscous Xylocaine EMLA EMLA Arrow-Lisinopril Douglas Lomide 2012 2014 2014 2014 2014 2012 2013 2014 2013 2013 2012 2012 31/12/13 2014 2013 2013 2012 2013 2014 2012 2012 2014 2014 2013 2014 2013 2013

Iron polymaltose Isosorbide mononitrate Isotretinoin Itraconazole Ketoconazole Lactulose Lamivudine Latanoprost Letrozole Levonorgestrel Lignocaine hydrochloride Lignocaine with prilocaine

Lisinopril Lithium carbonate Lodoxamide trometamol

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Loperamide hydrochloride Loratadine

Presentation

Cap 2 mg Oral liq 1 mg per ml Tab 10 mg Tab 1 mg & 2.5 mg Liq 0.5% Shampoo 1% Size 2 Tab 100 mg Tab 135 mg Tab 160 mg Tab 50 mg Suppos 500 mg Enema 1 g per 100 ml Tab immediate-release 500 mg & 850 mg Tab 5 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 25 mg per ml, 2 ml & 20 ml Tab 2.5 mg & 10 mg Tab 4 mg & 100 mg Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g Inj 5 mg per ml, 2 ml Tab 10 mg Crm 2% Tab 150 mg & 300 mg Crm 0.1% Oint 0.1% Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml

Brand Name Expiry Date*

Diamide Relief Lorapaed Loraclear Hayfever Relief Ativan A-Lices A-Lices EZ-fit Paediatric Mask De-Worm Colofac Apo-Megestrol Purinethol Asacol Pentasa Apotex Methatabs Biodone Biodone Forte Biodone Extra Forte Hospira Methoblastin Medrol Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Metamide Multichem Apo-Moclobemide m-Mometasone m-Mometasone RA-Morph RA-Morph RA-Morph RA-Morph 2013 2013

Lorazepam Malathion Mask for spacer device Mebendazole Mebeverine hydrochloride Megestrol acetate Mercaptopurine Mesalazine Metformin hydrochloride Methadone hydrochloride

2013 2013 2015 2014 2014 2012 2013 2014 2012 2012 2013 2012

Methotrexate Methylprednisolone Methylprednisolone sodium succinate

2013 2012 2012 2012

Metoclopramide hydrochloride Miconazole nitrate Moclobemide Mometasone furoate Morphine hydrochloride

2014 2014 2012 2012 2012

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Morphine sulphate

Presentation

Inj 5 mg per ml, 1 ml Inj 10 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Tab long-acting 10 mg, 30 mg, 60 mg & 100 mg Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg Tab immediate release 10 mg & 20 mg

Brand Name Expiry Date*

DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate Arrow-Morphine LA m-Elson Sevredol Hospira Konsyl-D Naphcon Forte Noflam 250 Noflam 500 Naltraccord AstraZeneca Viramune Suspension Viramune Habitrol Habitrol Habitrol Apo-Nicotinic Acid Arrow-Norfloxacin Primolut N Noriday 28 Nilstat Nilstat Nilstat Omezol Relief Midwest Dr Reddy’s Omeprazole Dr Reddy’s Ondansetron Dr Reddy’s Ondansetron Ox-Pam 2014 2014 2014 2012 2014 2013 2014 2012 2013 2013 2014 2012 2013 2014 2012 2014

2013

Morphine tartrate Mucilaginous laxatives Naphazoline hydrochloride Naproxen Natrexone hydrochloride Neostigmine Nevirapine

Inj 80 mg per ml, 1.5 ml & 5 ml Dry Eye drops 0.1% Tab 250 mg Tab 500 mg Tab 50 mg Inj 2.5 mg per ml, 1 ml Oral suspension 10 mg per ml Tab 200 mg

Nicotine

Gum 2 mg & 4 mg (classic, fruit, mint) Lozenge 1 mg & 2 mg Patch 7 mg, 14 mg & 21 mg Tab 50 mg & 500 mg Tab 400 mg Tab 5 mg Tab 350 µg Oral liq 100,000 u per ml Cap 500,000 u Tab 500,000 u Cap 10 mg, 20 mg & 40 mg Powder Inj 40 mg Tab disp 4 mg & 8 mg Tab 4 mg & 8 mg

2014

Nicotinic acid Norfloxacin Norethisterone Nystatin

Omeprazole

Ondansetron

2013

Oxazepam

Tab 10 mg & 15 mg

2014

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Oxytocin

Presentation

Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 40 mg Tab 20 mg & 40 mg Oral liq 250 mg per 5 ml Eye oint with soft white paraffin Tab 20 mg Low range & normal range Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Tab 0.25 mg & 1 mg Crm 5% Lotn 5% Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml

Brand Name Expiry Date*

Syntocinon Syntocinon Syntometrine Pantocid IV Dr Reddy’s Pantoprazole Paracare Double Strength Lacri-Lube Loxamine Breath-Alert Pegasys Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Permax Lyderm A-Scabies DBL Pethidine Hydrochloride DBL Pethidine Hydrochloride Cilicaine VK AFT AFT Apo-Pindolol Pizaccord Sandomigran Coloxyl Span-K Redipred Innovacon hCG One Step Pregnancy Test Cilicaine 2012 2012 2012 2014 2012 2012 2012 2014 2012

Pantoprazole

2014 2013 2014 2013 2013 2015 31/12/12

Paracetamol Paraffin liquid with soft white paraffin Paroxetine hydrochloride Peak flow meter Pegylated interferon alpha-2A

Pergolide Permethrin Pethidine hydrochloride

2014 2014 2014

Phenoxymethylpenicillin (Pencillin V)

Cap potassium salt 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 5 mg, 10 mg & 15 mg Tab 15 mg, 30 mg & 45 mg Tab 500 µg Oral drops 10% Tab long-acting 600 mg Oral liq 5 mg per ml Cassette Inj 1.5 mega u

2013

Pindolol Pioglitazone Pizotifen Poloxamer Potassium chloride Prednisone sodium phosphate Pregnancy tests – hCG urine Procaine penicillin

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Promethazine hydrochloride Pyridostigmine bromide Pyridoxine hydrochloride Quinine sulphate Ranitidine hydrochloride Rifabutin Ropinirole hydrochloride Roxithromycin Salbutamol

Presentation

Oral liq 5 mg per 5 ml Tab 60 mg Tab 25 mg Tab 50 mg Tab 300 mg Oral liq 150 mg per 10 ml Tab 150 mg & 300 mg Cap 150 mg Tab 0.25 mg, 1 mg, 2 mg & 5 mg Tab 150 mg & 300 mg Oral liq 2 mg per 5 ml Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratopium bromide 0.5 mg per vial, 2.5 ml Tab 5 mg Tab 50 mg & 100 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Inj 23.4%, 20 ml Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Grans effervescent 4 g sachets Eye drops 2% Nasal spray, 4% Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) Tab 80 mg & 160 mg 800 ml 230 ml (single patient) Tab 25 mg & 100 mg Inj 12 mg per ml, 0.5 ml Tab 50 mg & 100 mg Tab 20 mg Cap 400 µg

Brand Name Expiry Date*

Promethazine Winthrop Elixir Mestinon PyridoxADE Apo-Pyridoxine Q 300 Peptisoothe Arrow-Ranitidine Mycobutin Ropin ArrowRoxithromycin Salapin Asthalin Asthalin Duolin 2012 2014 2014 2012 2014 2013 2013 2012 2013 2012 2012

Salbutamol with ipratropium bromide Selegiline hydrochloride Sertraline Simvastatin

Apo-Selegiline Arrow-Sertraline Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg Biomed Micolette Ural Rexacrom Rex Genotropin Genotropin Mylan Volumatic Space Chamber Plus Spirotone Arrow-Sumatriptan Arrow-Sumatriptan Genox Tamsulosin-Rex

2012 2013 2014

Sodium chloride Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium cromoglycate Somatropin Sotalol Spacer device

2013 2013 2013 2013 2012 31/12/12 2012 2015

Spironolactone Sumatriptan Tamoxifen citrate Tamsulosin hydrochloride

2013 2013 2014 2013

Sole Subsidised Supply Products – cumulative to January 2012

Generic Name

Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terazosin hydrochloride Testosterone undecanoate Tetracosactrin Timolol maleate Tobramycin

Presentation

Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium, 500 ml & 1,000 ml Tab 10 mg Tab 1 mg, 2 mg & 5 mg Cap 40 mg Inj 250 µg Inj 1 mg per ml, 1 ml Tab 10 mg Eye drops 0.3% Eye oint 0.3% Inj 40 mg per ml, 2 ml Tab 100 mg Cap 50 mg Crm 0.02% Oint 0.02% 0.1% in Dental Paste USP Tab 500 mg Eye drops 0.5% & 1% Cap 5 mg Eye drops 0.25% Inj 500 mg Tab 40 mg & 80 mg Tab, strong, BPC Tab (BPC cap strength) Cap 100 mg Oral liq 10 mg per ml Caps 137.4 mg (50 mg elemental) Tab 7.5 mg

Brand Name Expiry Date*

Pinetarsol 2014

Normison Arrow Arrow-Testosterone Synacthen Synacthen Depot Apo-Timol Tobrex Tobrex DBL Tobramycin Tasmar Arrow-Tramadol Aristocort Aristocort Oracort Cycklokapron Mydriacyl Navoban Enuclene Mylan Isoptin B-PlexADE MultiADE Retrovir Retrovir Zincaps Apo-Zopiclone

2014 2013 2012 2014 2012 2014

Tolcapone Tramadol hydrochloride Triamcinolone acetonide

2014 2014 2014

Tranexamic acid Tropicamide Tropisetron Tyloxapol Vancomycin hydrochloride Verapamil hydrochloride Vitamin B complex Vitamins Zidovudine [AZT] Zinc sulphate Zopiclone January changes in bold

2013 2014 2012 2014 2014 2014 2013 2013 2013 2014 2014

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 January 2012

45 54 79 ATORVASTATIN – See prescribing guideline ❋ Tab 10 mg ............................................................................... 2.90 ❋ Tab 20 mg ............................................................................... 4.36 ❋ Tab 40 mg ............................................................................... 6.51 ❋ Tab 80 mg ............................................................................... 9.67 GLYCERYL TRINITRATE ❋ Aerosol spray 400 µg per dose – Up to 250 dose available on a PSO ............................................................................... 4.45 30 30 30 30 ✔ Dr Reddy’s Atorvastatin ✔ Dr Reddy’s Atorvastatin ✔ Dr Reddy’s Atorvastatin ✔ Dr Reddy’s Atorvastatin

250 dose OP ✔ Glytrin

CEFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. Inj 500 mg ............................................................................... 3.99 5 ✔ AFT Inj 1 g ...................................................................................... 3.99 5 ✔ AFT CEFUROXIME SODIUM Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement ..................................................................... 6.96 5 ✔ m-Cefuroxime Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. SULINDAC – Additional subsidy by Special Authority see SA1038 – Retail pharmacy ❋ Tab 100 mg ............................................................................. 2.66 50 (8.55) ❋ Tab 200 mg ............................................................................. 3.36 50 (15.10) TEMOZOLOMIDE – Special Authority see SA1063 – Retail pharmacy Cap 5 mg ............................................................................... 16.00 Cap 20 mg ............................................................................. 72.00 Cap 100 mg ......................................................................... 350.00 Cap 250 mg ......................................................................... 820.00 5 5 5 5

98 147

Aclin Aclin ✔ Temaccord ✔ Temaccord ✔ Temaccord ✔ Temaccord

Effective 14 December 2011

143 GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA1087 Inj 1 g .................................................................................... 62.50 1 ✔ DBL Gemcitabine

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 January 2012

187 Standard Supplements ➽ SA1104 Special Authority for Subsidy Initial application — (Children) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is under 18 years of age; and 2 Any of the following: 2.1 The patient has a condition causing malabsorption; or 2.2 The patient has failure to thrive; or 2.3 The patient has increased nutritional requirements; and 3 Nutrition goal has been set (eg reach a specific weight or BMI). Renewal — (Children) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is under 18 years of age; and 2 The treatment remains appropriate and the patient is benefiting from treatment; and 3 A nutrition goal has been set (eg reach a specific weight or BMI). Initial application — (Adults (This category cannot be processed electronically - fax paper copy)) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Any of the following: Patient is Malnourished 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or 1.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months; and 2 Any of the following: Patient has not responded to first-line dietary measures over a 4 week period by: 2.1 Increasing their food intake frequency (eg snacks between meals); or 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or 2.3 Using over the counter supplements (e.g. Complan); and 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI). Renewal —(Adults) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 A nutrition goal has been set (eg reach a specific weight or BMI); and 2 Any of the following: Patient is Malnourished 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or 2.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months. Initial application — (Adults transitioning from hospital Discretionary Community Supply) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... 1 The patient has had up to a 30 day supply of a 1.0 or a 1.5 kcal/ml Standard Oral Supplement; and 2 A nutrition goal has been set (eg reach a specific weight or BMI); and 3 Any of the following: Patient is Malnourished 3.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or 3.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or 3.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months. Initial application — (Specific medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 Is being feed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or 2 Malignancy and is considered likely to develop malnutrition as a result; or 3 Is undergoing a bone marrow transplant; or 4 Tempomandibular surgery. Renewal — (Specific medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 Is being fed via a nasogastric tube; or 2 Malignancy and is considered likely to develop malnutrition as a result; or 3 Has undergone a bone marrow transplant; or 4 Tempomandibular surgery. Initial application — (Chronic disease OR tube feeding) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or 2 Cystic Fibrosis; or 3 Liver disease; or 4 Chronic Renal failure; or 5 Inflammatory bowel disease; or 6 Chronic obstructive pulmonary disease with hypercapnia; or 7 Short bowel syndrome; or 8 Bowel fistula; or 9 Severe chronic neurological conditions. Renewal —(Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or 2 Cystic Fibrosis; or 3 Liver disease; or 4 Chronic Renal failure; or 5 Inflammatory bowel disease; or continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... 6 Chronic obstructive pulmonary disease with hypercapnia; or 7 Short bowel syndrome; or 8 Bowel fistula; or 9 Severe chronic neurological conditions. 196 EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA1112 – Hospital pharmacy [HP3] Powder .................................................................................. 15.21 450 g OP ✔ Pepti Junior Gold ➽ SA1112 Special Authority for Subsidy Initial application — (Transition from Old Form (SA0603)) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 The infant is currently receiving funded amino acid formula under Special Authority form SA0603; and 1.2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and 1.3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted; or 2 All of the following: 2.1 The patient is currently receiving funded extensively hydrolysed formula under Special Authority form SA0603; and 2.2 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and 2.3 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and 2.4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted. Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and 1.2 Either: 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or 2 Severe malabsorption; or 3 Short bowel syndrome; or 4 Intractable diarrhea; or 5 Biliary atresia; or 6 Cholestatic liver diseases causing malsorption; or 7 Chylous ascite; or 8 Chylothorax; or 9 Cystic fibrosis; or 10 Proven fat malabsorption; or 11 Severe intestinal motility disorders causing significant malabsorption; or 12 Intestinal failure. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. Renewal —(Step Down from Amino Acid Formula) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The infant is currently receiving funded amino acid formula; and 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 January 2012

40 53 53 53 54 72 FOLIC ACID ( subsidy) Oral liq 50 µg per ml ............................................................... 24.00 AMILORIDE ( subsidy) ‡ Oral liq 1 mg per ml ................................................................. 30.00 METHYLDOPA ( subsidy) ❋ Tab 125 mg ........................................................................... 14.25 ❋ Tab 250 mg ........................................................................... 15.10 ❋ Tab 500 mg ........................................................................... 23.15 SPIRONOLACTONE ( subsidy) ‡ Oral liq 5 mg per ml ................................................................. 30.00 CHLOROTHIAZIDE ( subsidy) ‡ Oral liq 50 mg per ml ............................................................... 26.00 DEXAMETHASONE ( subsidy) Oral liq 1 mg per ml – Retail pharmacy-Specialist ................... 45.00 Oral liq prescriptions: 1) Must be written by a Paediatrician or Paediatric Cardiologist; or 2) On the recommendation of a Paediatrician or Paediatric Cardiologist. TRIAMCINOLONE ACETONIDE ( subsidy) Inj 10 mg per ml, 1 ml ............................................................ 23.00 Inj 40 mg per ml, 1 ml ............................................................ 56.48 25 ml OP 25 ml OP 100 100 100 25 ml OP 25 ml OP 25 ml OP ✔ Biomed ✔ Biomed ✔ Prodopa ✔ Prodopa ✔ Prodopa ✔ Biomed ✔ Biomed ✔ Biomed

5 5

✔ Kenacort-A ✔ Kenacort-A40

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA1131 ( subsidy) Tab 250 mg ............................................................................. 4.19 14 (7.75) Klacid (7.75) Klamycin FLUCONAZOLE ( subsidy) Cap 50 mg – Retail pharmacy-Specialist ................................... 4.77 28 (6.82) Pacific Cap 150 mg – Subsidy by endorsement ................................... 0.91 1 (1.30) Pacific a) Maximum of 1 cap per prescription; can be waived by endorsement - Retail pharmacy - Specialist b) Patient has vaginal candida albicans and the practitioner considers that a topical imidazole (used intra vaginally) is not recommended and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist. Cap 200 mg – Retail pharmacy-Specialist ............................... 13.34 28 (19.05) Pacific TRIMETHOPRIM ( subsidy) ❋ Tab 300 mg – Up to 30 tab available on a PSO .......................... 8.94 50 ✔ TMP

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 January 2012 (continued)

85 METRONIDAZOLE ( subsidy) Tab 200 mg – Up to 30 tab available on a PSO ........................ 10.45 Tab 400 mg ........................................................................... 18.15 PARACETAMOL ( subsidy) ❋ Tab 500 mg – Up to 30 tab available on a PSO .......................... 9.38 DOXEPIN HYDROCHLORIDE ( subsidy) Cap 10 mg ............................................................................... 6.30 Cap 25 mg ............................................................................... 6.86 Cap 50 mg ............................................................................... 8.55 NORTRIPTYLINE HYDROCHLORIDE ( subsidy) Tab 10 mg ............................................................................... 6.69 Tab 25 mg ............................................................................. 14.77 CLONAZEPAM ( subsidy) Tab 500 µg .............................................................................. 6.68 Tab 2 mg ............................................................................... 12.75 BETAHISTINE DIHYDROCHLORIDE ( subsidy) ❋ Tab 16 mg ............................................................................. 10.00 TIMOLOL MALEATE ( subsidy) ❋ Eye drops 0.25% ...................................................................... 2.08 (2.37) ❋ Eye drops 0.5% ........................................................................ 2.08 (2.29) BIMATOPROST – Retail pharmacy-Specialist ( subsidy) See prescribing guideline ▲ Eye drops 0.03% .................................................................... 18.50 HYPROMELLOSE ( price) ❋ Eye drops 0.5% ........................................................................ 2.00 (3.92) 100 100 1,000 100 100 100 100 180 100 100 84 5 ml OP Apo-Timop 5 ml OP Apo-Timop ✔ Trichozole ✔ Trichozole ✔ Pharmacare ✔ Anten ✔ Anten ✔ Anten ✔ Norpress ✔ Norpress ✔ Paxam ✔ Paxam ✔ Vergo 16

116 118

119

121

125 167 168 169

3 ml OP 15 ml OP

✔ Lumigan

Methopt

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Sole Subsidised Supply

Effective 1 January 2012

For the list of new Sole Subsidised Supply products effective 1 January 2012 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 10-19.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 January 2012

29 39 74 OMEPRAZOLE ❋ Cap 10 mg ............................................................................... 0.97 ❋ Cap 20 mg ............................................................................... 1.26 ❋ Cap 40 mg ............................................................................... 1.86 CHARCOAL ❋ Tab 300 mg ............................................................................. 7.13 (9.77) OESTRADIOL ❋ TDDS 25 µg per day ................................................................. 3.01 (10.86) a) Higher subsidy of $10.86 per 8 patch with Special Authority see SA1018 b) No more than 2 patch per week c) Only on a prescription ❋ TDDS 50 µg per day ................................................................. 4.12 (13.18) a) Higher subsidy of $13.18 per 8 patch with Special Authority see SA1018 b) No more than 2 patch per week c) Only on a prescription ❋ TDDS 100 µg per day ............................................................... 7.05 (16.14) a) Higher subsidy of $16.14 per 8 patch with Special Authority see SA1018 b) No more than 2 patch per week c) Only on a prescription 30 30 30 ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole

100 Red Seal 8 Estraderm TTS 25

8 Estraderm TTS 50

8 Estraderm TTS 100

CLINDAMYCIN Inj phosphate 150 mg per ml, 4 ml – Retail pharmacySpecialist ............................................................................ 16.00 1 ✔ Dalacin C Note – Dalacin C inj phosphate 150 mg per ml, 4 ml, 10 injection pack remains listed. DARUNAVIR – Special Authority see SA1025 – Retail pharmacy Tab 300 mg ...................................................................... 1,190.00 120 ✔ Prezista

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 April 2012

80 CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA1131 Tab 250 mg ............................................................................. 4.19 14 (7.75) Klacid Klamycin FLUCONAZOLE Cap 50 mg – Retail pharmacy-Specialist ................................... 4.77 28 (6.82) Pacific Cap 150 mg – Subsidy by endorsement ................................... 0.91 1 (1.30) Pacific a Maximum of 1 cap per prescription; can be waived by endorsement - Retail pharmacy - Specialist b) Patient has vaginal candida albicans and the practitioner considers that a topical imidazole (used intravaginally) is not recommended and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist. Cap 200 mg – Retail pharmacy-Specialist ............................... 13.34 28 (19.05) Pacific PARACETAMOL ❋ Tab 500 mg – Up to 30 tab available on a PSO .......................... 9.38 TIMOLOL MALEATE ❋ Eye drops 0.25% ...................................................................... 2.08 (2.37) ❋ Eye drops 0.5% ........................................................................ 2.08 (2.29) 1,000 5 ml OP Apo-Timop 5 ml OP Apo-Timop ✔ Pharmacare

116 167

Effective 1 July 2012

50 98 DIGOXIN ❋ Tab 62.5 µg – Up to 30 tab available on a PSO .......................... 5.56 200 ✔ Lanoxin PG ❋ Tab 250 µg – Up to 30 tab available on a PSO ........................... 6.05 100 ✔ Lanoxin Note – Lanoxin PG tab 62.5 µg, 240 tab pack, and Lanoxin tab 250 µg 240 tab pack, remain subsidised. SULINDAC – Additional subsidy by Special Authority see SA1038 – Retail pharmacy ❋ Tab 100 mg ............................................................................. 5.32 100 (17.10) ❋ Tab 200 mg ............................................................................. 6.72 100 (30.20)

Daclin Daclin

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 January 2012

17 19 AMILORIDE ( price) Oral liq 1 mg per ml ................................................................ 30.00 ATORVASTATIN Tab 10 mg ................................................................................ 2.90 Tab 20 mg ................................................................................ 4.36 Tab 40 mg ................................................................................ 6.51 Tab 80 mg ................................................................................ 9.67 20 23 23 BETAHISTINE DIHYDROCHLORIDE ( price) Tab 16 mg ............................................................................. 10.00 CEFACLOR MONOHYDRATE (removal of HSS) Cap 250 mg – 1% DV Mar-12 to 2013 ..................................... 24.57 25 ml 30 30 30 30 Biomed Dr Reddy’s Atorvastatin Dr Reddy’s Atorvastatin Dr Reddy’s Atorvastatin Dr Reddy’s Atorvastatin Vergo 16 Cefaclor Sandoz AFT AFT

84 100

CEFAZOLIN SODIUM Inj 500 mg – 1% DV Mar-12 to 2014 ........................................ 3.99 5 Inj 1 g – 1% DV Mar-12 to 2014 ............................................... 3.99 5 Note – Hospira cefazolin sodium inj 500 mg and 1 g to be delisted 1 March 2012. CEFUROXIME SODIUM Inj 750 mg – 1% DV Mar-12 to 2014 ........................................ 6.96 Note – Zinacef inj 750 mg to be delisted 1 March 2012. CHLORHEXIDINE IN ALCOHOL Soln 2% with 70% alcohol, 500 ml (tinted red) ...................... 114.72 CHLOROTHIAZIDE ( price) Oral liq 50 mg per ml .............................................................. 26.00 CLARITHROMYCIN (HSS delayed) Tab 500mg – 1% DV Apr-12 Jan-12 to 2014 ........................... 10.95 CLONAZEPAM ( price) Tab 500 µg ............................................................................... 6.68 Tab 2 mg ................................................................................ 12.75 DEXAMETHASONE ( price) Oral liq 1 mg per ml ................................................................ 45.00 EFAVIRENZ Tab 50 mg ............................................................................ 158.33 Tab 200 mg .......................................................................... 474.99 Tab 600 mg .......................................................................... 474.99 5

m-Cefuroxime

24 24 25 25

12 25 ml 14 100 100 25 ml 30 90 30

healthE Biomed Apo-Clarithromycin Paxam Paxam Biomed Stocrin Stocrin Stocrin

28 30

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 January 2012 (continued)

34 36 FOLIC ACID ( price) Oral liq 50 µg per ml ............................................................... 24.00 25 ml Biomed

GLYCERYL TRINITRATE Aerosol spray 400 µg per dose – 1% DV Mar-12 to 2014 ......... 4.45 250 dose Glytrin Note – Nitrolingual Pumpspray aerosol spray 400 µg per dose to be delisted 1 March 2012. HYPROMELLOSE ( price) Eye drops 0.5% ......................................................................... 3.92 IMIPENEM WITH CILASTATIN ( price) Inj 500 mg with cilastatin 500 mg ........................................... 18.37 MEROPENEM Inj 500 mg – 1% DV Mar-12 to 2014 ...................................... 10.50 Inj 1 g – 1% DV Mar-12 to 2014 ............................................. 21.00 Note – Merrem inj 500 mg and 1 g to be delisted 1 March 2012. METHYLDOPA ( price) Tab 125 mg ........................................................................... 14.25 Tab 250 mg ........................................................................... 15.10 Tab 500 mg ........................................................................... 23.15 METRONIDAZOLE ( price) Tab 200 mg ........................................................................... 10.45 Tab 400 mg ........................................................................... 18.15 NORTRIPTYLINE HYDROCHLORIDE ( price) Tab 10 mg ............................................................................... 6.69 Tab 25 mg ............................................................................. 14.77 SODIUM CHLORIDE ( price) Inj 0.9%, 10 ml ........................................................................ 11.50 SPIRONOLACTONE ( price) Oral liq 5 mg per ml ................................................................ 30.00 15 ml 1 1 1 Methopt Primaxin Penembact Penembact

38 38 44

100 100 100 100 100 100 250 50 25 ml

Prodopa Prodopa Prodopa Trichozole Trichozole Norpress Norpress Multichem Biomed Temaccord Temaccord Temaccord Temaccord

59 60 61

TEMOZOLOMIDE Cap 5 mg – 1% DV Mar-12 to 2014 ........................................ 16.00 5 Cap 20 mg – 1% DV Mar-12 to 2014 ...................................... 72.00 5 Cap 100 mg – 1% DV Mar-12 to 2014 .................................. 350.00 5 Cap 250 mg – 1% DV Mar-12 to 2014 .................................. 820.00 5 Note – Temodal cap 5 mg, 20 mg, 100 mg and 250 mg to be delisted 1 March 2012. TRIAMCINOLONE ACETONIDE ( price) Inj 10 mg per ml, 1 ml ............................................................ 23.00 Inj 40 mg per ml, 1 ml ............................................................ 56.48 5 5

Kenacort-A Kenacort-A40

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 January 2012 (continued)

63 TRIAMCINOLONE ACETONIDE Inj 10 mg per ml, 5 ml ............................................................. 10.31 1 Kenacort-A Inj 40 mg per ml, 5 ml ............................................................. 23.44 1 Kenacort-A40 Note – Kenacort-A inj 10 mg per ml, 5 ml and Kenacort-A40 inj 40 mg per ml, 5 ml delisted 1 January 2012. TRIMETHOPRIM ( price) Tab 300 mg ............................................................................. 8.94 50 TMP

Effective 14 December 2011

35 GEMCITABINE HYDROCHLORIDE Inj 1 g ..................................................................................... 62.50 1 DBL Gemcitabine

Effective 1 December 2011

17 20 AMLODIPINE Tab 2.5 mg – 1% DV Mar-12 to 2014 ...................................... 2.45 BETAMETHASONE DIPROPRIONATE WITH CALCIPOTRIOL Oint 500 µg with calcipotriol 50 µg .......................................... 26.12 Topical gel 500 µg with calcipotriol 50 µg ............................... 26.12 CALCIPOTRIOL ( price) Crm 50 µg per g ..................................................................... 16.00 45.00 Oint 50 µg per g ...................................................................... 45.00 Soln 50 µg per ml .................................................................. 16.00 CALCIUM CARBONATE Tab 1.25 g (500 mg elemental) – 1% DV Feb-12 to 2014 .......... 6.38 CEFACLOR MONOHYDRATE (Addition of HSS) Cap 250 mg – 1% DV Mar-12 to 2013 .................................... 24.57 DANTROLENE SODIUM HEMIHEPTAHYDRATE Inj 20 mg ............................................................................. 800.00 FUSIDIC ACID ( price) Eye drops 1% ........................................................................... 4.50 GLYCERIN WITH SODIUM SACCHARIN ( price) Suspension ............................................................................. 36.80 GLYCERIN WITH SUCROSE ( price) Suspension ........................................................................... 36.80 MASK FOR SPACER DEVICE Size 2 ........................................................................................ 2.99 100 30 g 30 g 30 g 100 g 100 g 30 ml 250 100 6 5g 473 ml 473 ml 1 Apo-Amlodipine Daivobet Daivobet Daivonex Daivonex Daivonex Daivonex Arrow-Calcium Cefaclor Sandoz Dantrium IV Fucithalmic Ora-Sweet SF Ora-Sweet EZ-fit Paediatric Mask

22 23 27 34 36 36 42

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 December 2011 (continued)

45 45 45 46 METHYLCELLULOSE ( price) Suspension ............................................................................. 36.80 473 ml Ora-Plus Ora-Blend SF Ora-Blend Solu-Medrol Solu-Medrol Lopresor Paclitaxel Actavis Paclitaxel Actavis Paclitaxel Actavis

METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN ( price) Suspension ............................................................................ 36.80 473 ml METHYLCELLULOSE WITH GLYCERIN AND SUCROSE ( price) Suspension ............................................................................ 36.80 METHYLPREDNISOLONE SODIUM SUCCINATE Inj 40 mg per ml, 1 ml – 1% DV Dec-09 to 2012 ....................... 6.06 Inj 62.5 mg per ml, 2 ml – 1% DV Dec-09 to 2012 .................. 16.50 METOPROLOL TARTRATE Inj 1 mg per ml, 5 ml ............................................................... 24.00 PACLITAXEL Inj 100 mg .............................................................................. 91.67 Inj 150 mg ........................................................................... 137.50 Inj 300 mg ........................................................................... 275.00 Note – HSS still remains on Paclitaxel Ebewe PEAK FLOW METER Low Range .............................................................................. 11.44 Normal Range ......................................................................... 11.44 QUININE SULPHATE Tab 200 mg ............................................................................ 17.20 Note – Q 200 tab 200 mg to be delisted 1 February 2012. 473 ml 1 1 5 1 1 1

46 50

1 1 250

Breath-Alert Breath-Alert Q 200

REMIFENTANIL HYDROCHLORIDE (delayed HSS and delisting) Inj 1 mg vial – 1% DV Feb Jan-12 to 2014 ............................. 27.95 5 Remifentanil-AFT 50.75 Ultiva Inj 2 mg vial – 1% DV Feb Jan -12 to 2014 ............................ 41.80 5 Remifentanil-AFT 101.50 Ultiva Note – HSS for Remifentanil-AFT delayed from January 2012 until February 2012. The delisting of Ultiva inj 1 mg and 2 mg has also been delayed until 1 February 2012. SPACER DEVICE 230 ml (single patient)............................................................... 4.72 TESTOSTERONE CYPIONATE ( price) Inj long-acting 100 mg per ml, 10 ml – 1% DV Feb-12 to 2014 .................................................... 76.50 1 Space Chamber Plus

60 62

Depo-Testosterone

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to General Rules

Effective 1 December 2011

14 Discretionary Community Supply Pharmaceuticals 7.5 Subject to rules 7.6 and 7.7, DHB Hospitals must not fund for use in the community, any pharmaceuticals that are not Discretionary Community Supply Pharmaceuticals unless they have been approved under Hospital Exceptional Circumstances. 7.6 DHB Hospitals may fund from their own budgets, any Pharmaceutical that is listed in Sections A-G of the Pharmaceutical Schedule without Hospital Exceptional Circumstances (HEC) approval provided that: a) the quantity supplied does not exceed that sufficient for: i) up to 5 days treatment, or one original pack (where appropriate to provide less); or ii) more than 5 days treatment, provided that the relevant DHB Hospital has a dispensing for discharge policy and the quantity supplied is in accordance with that policy; and b) the Pharmaceutical is supplied consistent with any restrictions applying to that Pharmaceutical in Sections A-G of the Pharmaceutical Schedule. 7.7 DHB Hospitals may fund from their own budgets any Pharmaceutical without Hospital Exceptional Circumstances approval provided that the Pharmaceutical is only being supplied to the patient for them to use in the 24 hours leading up to a procedure to be performed in a DHB Hospital.

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Index

Pharmaceuticals and brands A Aclin .................................................................. 20 Amiloride ..................................................... 25, 30 Amlodipine......................................................... 32 Anten ................................................................. 26 Apo-Amlodipine ................................................. 32 Apo-Clarithromycin ............................................ 30 Apo-Timop................................................... 26, 29 Arrow-Calcium ................................................... 32 Atorvastatin.................................................. 20, 30 B Betahistine dihydrochloride........................... 26, 30 Betamethasone diproprionate with calcipotriol .... 32 Bimatoprost ....................................................... 26 Breath-Alert........................................................ 33 C Calcipotriol......................................................... 32 Calcium carbonate ............................................. 32 Cefaclor monohydrate .................................. 30, 32 Cefaclor Sandoz ........................................... 30, 32 Cefazolin sodium ......................................... 20, 30 Cefuroxime sodium ...................................... 20, 30 Charcoal ............................................................ 28 Chlorhexidine in alcohol...................................... 30 Chlorothiazide .............................................. 25, 30 Clarithromycin........................................ 25, 29, 30 Clindamycin ......................................................... 28 Clonazepam ................................................. 26, 30 D Daclin ................................................................ 29 Dalacin C ........................................................... 28 Daivobet ............................................................ 32 Daivonex ............................................................ 32 Dantrium IV ........................................................ 32 Dantrolene sodium hemiheptahydrate ................. 32 Darunavir ............................................................. 28 DBL Gemcitabine ......................................... 20, 32 Depo-Testosterone............................................. 33 Dexamethasone ........................................... 25, 30 Digoxin ................................................................ 29 Doxepin hydrochloride........................................ 26 Dr Reddy’s Atorvastatin................................ 20, 30 Dr Reddy’s Omeprazole...................................... 28 E Efavirenz ............................................................ 30 Estraderm TTS 100 ............................................ 28 Estraderm TTS 25 .............................................. 28 Estraderm TTS 50 .............................................. 28 Extensively hydrolysed formula........................... 23 EZ-fit Paediatric Mask......................................... 32 F Fluconazole .................................................. 25, 29 Folic acid ..................................................... 25, 31 Fucithalmic ........................................................ 32 Fusidic acid........................................................ 32 G Gemcitabine hydrochloride ........................... 20, 32 Glycerin with sodium saccharin .......................... 32 Glycerin with sucrose ......................................... 32 Glyceryl trinitrate .......................................... 20, 31 Glytrin .......................................................... 20, 31 H Hypromellose............................................... 26, 31 I Imipenem with cilastatin ..................................... 31 K Kenacort-A............................................. 25, 31, 32 Kenacort-A40......................................... 25, 31, 32 Klacid .......................................................... 25, 29 Klamycin...................................................... 25, 29 L Lanoxin .............................................................. 29 Lanoxin PG ........................................................ 29 Lopresor ............................................................ 33 Lumigan ............................................................ 26 M m-Cefuroxime .............................................. 20, 30 Mask for spacer device ...................................... 32 Meropenem ....................................................... 31 Methopt ....................................................... 26, 31 Methylcellulose .................................................. 33 Methylcellulose with glycerin and sodium saccharin............................................ 33 Methylcellulose with glycerin and sucrose .......... 33 Methyldopa .................................................. 25, 31 Methylprednisolone sodium succinate ................ 33 Metoprolol tartrate .............................................. 33 Metronidazole .............................................. 26, 31 N Norpress ...................................................... 26, 31 Nortriptyline hydrochloride............................ 26, 31 O Oestradiol .......................................................... 28 Omeprazole........................................................ 28 Ora-Blend .......................................................... 33 Ora-Blend SF...................................................... 33 Ora-Plus ............................................................ 33 Ora-Sweet.......................................................... 32 Ora-Sweet SF ..................................................... 32 P Paclitaxel ........................................................... 33 Paclitaxel Actavis ............................................... 33 Paracetamol................................................. 26, 29 Paxam ......................................................... 26, 30

Index

Pharmaceuticals and brands Peak flow meter ................................................. 33 Penembact......................................................... 31 Pepti Junior Gold................................................ 23 Pharmacare ................................................. 26, 29 Prezista.............................................................. 28 Primaxin ............................................................ 31 Prodopa ....................................................... 25, 31 Q Q 200 ................................................................ 33 Quinine sulphate ................................................ 33 R Remifentanil-AFT................................................ 33 Remifentanil hydrochloride ................................. 33 S Sodium chloride ................................................. 31 Solu-Medrol ....................................................... 33 Space Chamber Plus .......................................... 33 Spacer device .................................................... 33 Spironolactone ............................................. 25, 31 Stocrin ............................................................... 30 Sulindac....................................................... 20, 29 T Temaccord .................................................. 20, 31 Temozolomide ............................................. 20, 31 Testosterone cypionate ...................................... 33 Timolol maleate............................................ 26, 29 Triamcinolone acetonide ........................ 25, 31, 32 Trichozole .................................................... 26, 31 Trimethoprim ............................................... 25, 32 U Ultiva ................................................................. 33 V Vergo 16 ...................................................... 26, 30

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 January 2012

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 January 2012 Section H cumulative for December 2011 and January 2012 Contents Summary of Pharmac decisions effective 1 January 2012 … 3 Subsidy changes for some respiratory inhalation products and…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.